Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial

Leukemia. 2023 Mar;37(3):699-701. doi: 10.1038/s41375-023-01809-z. Epub 2023 Jan 12.
No abstract available

Publication types

  • Multicenter Study
  • Clinical Trial, Phase II
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols
  • Dexamethasone
  • Humans
  • Multiple Myeloma* / drug therapy
  • Neoplasm Recurrence, Local / drug therapy
  • Neoplasms, Plasma Cell*
  • Thalidomide

Substances

  • pomalidomide
  • Thalidomide
  • Dexamethasone